Ownership history in PRUDENTIAL FINANCIAL INC Β· 9 quarters on record
This page tracks every 13F SEC filing in which PRUDENTIAL FINANCIAL INC reported a position in XENON PHARMACEUTICALS INC (XENE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π PRUDENTIAL FINANCIAL INC underperformed the S&P 500 by β26.2% annually on this XENE position. Timing score: 40% (2/5 decisions correct). Average cost basis: $41.49. Maximum drawdown during holding period: β32.0%.
β Significantly underperformed the S&P 500 by 26.2% ann.
7 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 5 add/trim decisions correct
Best entry: $31.30 (2025 Q2) Β· Worst: $46.06 (2023 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
4 adds Β· 3 trims. Bought during 2 of 5 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size